Faze Medicines, a biotech built by Third Rock, to shutter - STAT

2 years ago 48
  • Allison DeAngelis

By Allison DeAngelis Nov. 8, 2022

Reprints

Adobe

A biotech institution that hoped to usage compartment biology to code neurological disorders is shutting down.

Faze Medicines was built by VC Third Rock Ventures and launched successful 2020 with $81 cardinal from Third Rock, Casdin Capital, and task funds tally by cause giants Novartis, Eli Lilly, and AbbVie.

Unlock this nonfiction by subscribing to STAT+ and bask your archetypal 30 days free!

GET STARTED

About the Author Reprints

Allison DeAngelis

Allison DeAngelis

Biotech Startups and Venture Capital Reporter

Allison is simply a biotech newsman astatine STAT, covering biopharma startups and task capital.

Read Entire Article